The Dyspepsia (Indigestion) drugs in development market research report provides comprehensive information on the therapeutics under development for Dyspepsia (Indigestion), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Dyspepsia (Indigestion). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Dyspepsia (Indigestion) and features dormant and discontinued products.
GlobalData tracks 12 drugs in development for Dyspepsia (Indigestion) by 14 companies/universities/institutes. The top development phase for Dyspepsia (Indigestion) is phase ii with four drugs in that stage. The Dyspepsia (Indigestion) pipeline has ten drugs in development by companies and two by universities/ institutes. Some of the companies in the Dyspepsia (Indigestion) pipeline products market are: Korea United Pharm, Renexxion and Sinovant Sciences HK.
The key targets in the Dyspepsia (Indigestion) pipeline products market include Potassium Transporting ATPase Alpha Chain 1, Motilin Receptor, and Substance P Receptor.
The key mechanisms of action in the Dyspepsia (Indigestion) pipeline product include Motilin Receptor Agonist with one drug in Preclinical. The Dyspepsia (Indigestion) pipeline products include one routes of administration with the top ROA being Oral and one key molecule types in the Dyspepsia (Indigestion) pipeline products market including Small Molecule.
Dyspepsia (Indigestion) overview
Indigestion is a group of gastrointestinal symptoms that occur together, including pain, a burning feeling, or discomfort in the upper abdomen; feeling full too soon while eating; and feeling uncomfortable after eating. Treatment for indigestion depends on the cause and may include medicines, changes in what you eat and drink, psychological therapies, and lifestyle changes.
For a complete picture of Dyspepsia (Indigestion)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
